Literature DB >> 16507003

Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?

N Bons1, F Rieger, D Prudhomme, A Fisher, K-H Krause.   

Abstract

Age-associated dementia, in particular Alzheimer's disease (AD), will be a major concern of the 21st century. Research into normal brain aging and AD will therefore become increasingly important. As for other areas of medicine, the availability of good animal models will be a limiting factor for progress. Given the complexity of the human brain, the identification of appropriate primate models will be essential to further knowledge of the disease. In this review, we describe the features of brain aging and age-associated neurodegeneration in a small lemurian primate, the Microcebus murinus, also referred to as the mouse lemur. The mouse lemur has a relatively short life expectancy, and animals over 5 years of age are considered to be elderly. Among elderly mouse lemurs, the majority show normal brain aging, whereas approximately 20% develop neurodegeneration. This Microcebus age-associated neurodegeneration is characterized by a massive brain atrophy, abundant amyloid plaques, a cytoskeletal Tau pathology and a loss of cholinergic neurons. While elderly mouse lemurs with normal brain aging maintain memory function and social interaction, animals with age-associated neurodegeneration lose their cognitive and social capacities and demonstrate certain similarities with age-associated human AD. We conclude that M. murinus is an interesting primate model for the study of normal brain aging and the biochemical dysfunctions occurring in age-associated neurodegeneration. Mouse lemurs might also become an increasingly important model for the development of novel treatments in this domain.

Entities:  

Mesh:

Year:  2006        PMID: 16507003     DOI: 10.1111/j.1601-183X.2005.00149.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  42 in total

Review 1.  Nonhuman primate models of Alzheimer-like cerebral proteopathy.

Authors:  Eric Heuer; Rebecca F Rosen; Amarallys Cintron; Lary C Walker
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Optimization of volumetric computed tomography for skeletal analysis of model genetic organisms.

Authors:  Sergio X Vasquez; Mark S Hansen; Ali N Bahadur; Matthew F Hockin; Gordon L Kindlmann; Lisa Nevell; Isabel Q Wu; David J Grunwald; David M Weinstein; Greg M Jones; Christopher R Johnson; John L Vandeberg; Mario R Capecchi; Charles Keller
Journal:  Anat Rec (Hoboken)       Date:  2008-05       Impact factor: 2.064

3.  Age-associated cerebral atrophy in mouse lemur primates.

Authors:  Audrey Kraska; Olene Dorieux; Jean-Luc Picq; Fanny Petit; Emmanuel Bourrin; Evelyne Chenu; Andreas Volk; Martine Perret; Philippe Hantraye; Nadine Mestre-Frances; Fabienne Aujard; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2009-06-28       Impact factor: 4.673

Review 4.  The development of small primate models for aging research.

Authors:  Kathleen E Fischer; Steven N Austad
Journal:  ILAR J       Date:  2011

5.  Hearing and age-related changes in the gray mouse lemur.

Authors:  Christian Schopf; Elke Zimmermann; Julia Tünsmeyer; Sabine B R Kästner; Peter Hubka; Andrej Kral
Journal:  J Assoc Res Otolaryngol       Date:  2014-08-12

Review 6.  Primate aging in the mammalian scheme: the puzzle of extreme variation in brain aging.

Authors:  Caleb E Finch; Steven N Austad
Journal:  Age (Dordr)       Date:  2012-01-05

Review 7.  Enhancing our brains: Genomic mechanisms underlying cortical evolution.

Authors:  Caitlyn Mitchell; Debra L Silver
Journal:  Semin Cell Dev Biol       Date:  2017-08-31       Impact factor: 7.727

Review 8.  Age-related decline in executive function as a hallmark of cognitive ageing in primates: an overview of cognitive and neurobiological studies.

Authors:  Agnès Lacreuse; Naftali Raz; Daniel Schmidtke; William D Hopkins; James G Herndon
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-09-21       Impact factor: 6.237

Review 9.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Natural non-trasgenic animal models for research in Alzheimer's disease.

Authors:  Manuel Sarasa; Pedro Pesini
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.